|
|
|
| home > ebr > current issue |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
Surfacing Missed Opportunities
David Gwyn at Amplexor
There are five areas in which richer, more holistic product information could shine a light into the life science industry’s blind spots and help transform business outcomes
|
|
|
|
Base Editing and Its Application to Cell and Gene Therapy
Dr Ceri Wiggins at Horizon Discovery
CRISPR-Cas gene editing has been a force to be reckoned with in gene engineering for years, and it doesn’t seem likely this is going to change anytime soon
|
|
|
|
Nova Biomedical FLEX®2
With over 1,300 employees and manufacturing facilities in Waltham and Billerica, Massachusetts, and Taipei, Taiwan, Nova Biomedical is one of the 25 largest in vitro diagnostic companies in the world and the largest privately owned in vitro diagnostic company in the US
|
|
|
|
|
Risk Management for Analytical Method Development
Madalena R Testas, Daniela B Santos, and José C Menezes at 4Tune Engineering
In the biopharmaceutical industry, analytical methods are among the most critical elements for process monitoring and product release
|
|
|
|
Beyond Big Data
Joern Klinger at biotx.ai
We can’t always rely on Big Data to be available; therefore, it’s worth suggesting ways of still effectively applying machine learning when that’s the case
|
|
|
|
Genotoxic Impurities in Drug Products: Review of Nitrosamine Assays
Elodie Barrau, Emmanuel Desmartin, Valentina Paschetta, Davide Tartaglione, Mònica Coll Furest, and Ana Novak at Eurofins
In the past couple of years, the prevalence of nitrosamines in drug substances has made them a hot topic of conversation in the medical industry
|
|
|
|
|
|
The Quest for a Cure
David Wilson at Avacta
It's of little doubt that there is a great need for the development of rapid diagnostic tests to tackle the COVID-19 pandemic
|
|
|
|
Leveraging Health Data to Support Patient Care
Gilles Paubert at Cegedim Health Data
There are some key areas where current real-world data can add immediate value to patients, the healthcare system, and our economies
|
|
|
|
Would Greater Diversity and Inclusion Improve Innovation?
Stephen Frost at Frost Included
The pharma industry is responsible for great strides in world health, yet it’s undeniable that there are still many more goals to accomplish, and a lack of diversity may be holding it back
|
|
|
|
A Conversation with an Expert in Drug Development
As the world grapples with the impact of the COVID-19 pandemic, the life science industry and regulators are racing to find an effective treatment. We spoke with Colin Orford, Senior Vice President of Drug Development services at ICON plc about the direction that this work is taking
|
|
|
|
|
|
The Promise of Drug Discovery
The past few decades have seen large strides in the medical industry, but there are still many patients suffering with unmet medical needs that could benefit from further innovation, especially in drug discovery. EBR spoke to Dr Craig Fox, CSO at C4X Discovery, to ask about his thoughts on the subject
|
|
|
|
Microphysiological Systems Emerging as Powerful Tools for Drug Discovery
Dr Audrey Dubourg at CN Bio
A new class of in vitro model is expected to assist drug discovery by providing robust physiologically relevant data at critical stages of R&D
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Analytical Toolbox for Cell and Gene Therapy development
We guide you through the emerging field of gene therapy developments
More info >> |
|
 |
White Papers |
 |
|
Case Study: Cmed’s Mobile Data Management Solution
Cmed Clinical Services
The trial presented to Cmed was a randomized, double blinded, placebo
and active controlled study to evaluate the cardiac safety of multiple
doses of [study drug] in health volunteers.
The pharmaceutical
company, who were into the second year of development of a potential
blockbuster compound for the treatment of chronic myelogenous leukaemia
(CML), were requested by the FDA to design a trial to provide
information on the cardiac safety of different dose levels of the study
drug in healthy adult volunteers. The primary objective of the study was
specifically to find the maximum tolerated dose before QTc levels
became unsafe. All development of the compound was put on hold until the
results of this study were submitted to the FDA and approval granted
for the compound to progress into full development.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
_1.jpg)
.jpg)
